Aoquan focuses on developing new dosage forms, indications, and administration methods for existing drugs to meet unmet clinical needs.

ASN001 is a non-selective beta-adrenergic receptor blocker developed for treating infantile hemangioma, with completed clinical trials in China and communication with regulatory bodies for market approval.